Management of Bisphosphonate-Related Osteonecrosis of the Jaw With a Platelet-Rich Fibrin Membrane: Technical Report

Soydan, Sıdıka Sinem; Uçkan, Sina

doi:10.1016/j.joms.2013.07.027

Cited by 63 publications

(36 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies including small numbers of patients have been conducted to examine treatment with hyperbaric oxygen therapy [20], platelet-rich plasma [21], low-level laser irradiation [22], parathyroid hormone [23], and bone morphogenic protein [24]. Recent animal studies have demonstrated that intravenous injection (I.V.)…”

Section: Introductionmentioning

confidence: 99%

Multipotent mesenchymal stromal cell sheet therapy for bisphosphonate-related osteonecrosis of the jaw in a rat model

et al. 2016

View full text Add to dashboard Cite

Bisphosphonates are frequently used to treat osteoporosis, bone metastasis of various cancers, and other diseases. However, bisphosphonate related-osteonecrosis of the jaw (BRONJ) is an intractable disease because it often recurs after surgery or is exacerbated following conservative treatment. Therefore, an alternative approach for treating BRONJ is needed. In this study, we developed a bone marrow-derived multipotent mesenchymal stromal cell (MSC) sheet to treat BRONJ and investigated the effect of MSC sheet transplantation in a rat model of BRONJ-like disease. The MSC sheet transplantation group showed wound healing in most cases, while only minimal healing was observed in the control group and MSC intravenous injection group. Our results suggest that the MSC sheet is a promising alternative approach for the treatment of BRONJ.

show abstract

Section: Introductionmentioning

confidence: 99%

Multipotent mesenchymal stromal cell sheet therapy for bisphosphonate-related osteonecrosis of the jaw in a rat model

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Regarding the cases presented herein using PRP and LPRF, in the follow-up of 4 and 6 months, both patients had not presented complete healing of the surgical wound which has a different outcome that literature reports with BRONJ cases (27,28). This may be justified by the observation of Zebaze et al (32), who reported that denosumab reduced remodeling more rapidly and more completely than alendronate.…”

Section: Denosumab Osteonecrosis Of the Jawmentioning

confidence: 68%

“…Studies associating LPRF with osteonecrosis of the jaw are scarce and in two of them (28,30) the antiresorptive agents were bisphosphonates unlike our cases where they were used the Denosumab (Case 1) and Denosumab with Bevacizumab (Case 2). Despite the new AAOMS recommendations, success rates of conservative treatment regimens range from less than 20% to over 50%, which is significantly lower than the success rate of over 85% reported for surgical therapy approaches.…”

Section: Denosumab Osteonecrosis Of the Jawmentioning

confidence: 71%

Surgery Combined with LPRF in Denosumab Osteonecrosis of the Jaw: Case Report

et al. 2016

View full text Add to dashboard Cite

This paper describes two cases in which the use of leucocyte-rich and platelet-rich fibrin (LPRF) combined with bone resection did not result in complete tissue response in the treatment of medication-related osteonecrosis of the jaw (MRONJ). It has been recently described in patients receiving subcutaneous administration of RANK-inhibitors, such as Denosumab, and anti-angiogenic drugs, such as Bevacizumab, as observed in our cases. Due to promising results in recent studies, more patients will receive these medications in order to avoid skeletal complications due to metastatic bone disease and, therefore, this scenario has a potential to become a comparable challenge to the bisphosphonateinduced jaw necrosis in the area of Oral and Maxillofacial Surgery. No convincing surgical technique has been described to overcome the non-healing mucosal lesions with exposed bone due to RANK-inhibitor therapy. Based on the findings in the literature and in both cases described herein can be concluded that the use of LPRF should be considered in the treatment of patients with DRONJ. S u r g e r y C o m b i n e d w i t h L P R F i n D e n o s u m a b O s t e o n e c r o s i s o f t h e J a w : C a s e R e p o r t

show abstract

“…49,[51][52] Other authors propose the application of plasma rich in growth factors as an alternative therapy in order to stimulate the angiogenesis and repair of the local bone tissue. [67][68][69] Decisions should be made by a complete multidisciplinary team (oral and maxillofacial surgeon, oncologist, and rheumatologist) on the basis of the current clinical stage according to the AAOMS. 51,70 …”

Section: Discussionmentioning

confidence: 99%

Osteonecrosis of the Jaw Related to Oral Bisphosphonate Treatment: A Clinical Case

García-Ávila¹,

Hernández-Montero²,

Cruz-Perez³

et al. 2014

Dent Open J

View full text Add to dashboard Cite

Management of Bisphosphonate-Related Osteonecrosis of the Jaw With a Platelet-Rich Fibrin Membrane: Technical Report

Cited by 63 publications

References 26 publications

Multipotent mesenchymal stromal cell sheet therapy for bisphosphonate-related osteonecrosis of the jaw in a rat model

Multipotent mesenchymal stromal cell sheet therapy for bisphosphonate-related osteonecrosis of the jaw in a rat model

Surgery Combined with LPRF in Denosumab Osteonecrosis of the Jaw: Case Report

Osteonecrosis of the Jaw Related to Oral Bisphosphonate Treatment: A Clinical Case

Contact Info

Product

Resources

About